Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nuwellis ( (NUWE) ) has shared an announcement.
On August 21, 2025, Nuwellis, Inc. announced that it has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). This clearance may enhance the company’s product offerings and potentially improve its market position in the medical device industry.
The most recent analyst rating on (NUWE) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While there are positive strategic initiatives and corporate events, the immediate financial challenges and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Average Trading Volume: 1,058,436
Technical Sentiment Signal: Sell
Current Market Cap: $5.38M
See more insights into NUWE stock on TipRanks’ Stock Analysis page.